Mid Pharma Sector In-licensing and Other Externalization Strategies by variablepitch336

VIEWS: 51 PAGES: 6

									Brochure
More information from http://www.researchandmarkets.com/reports/340358/

Mid Pharma Sector: In-licensing and Other Externalization Strategies
Description: Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition. Scope of this title: - Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus - Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios - Examination of which types of externalization strategy are most popular in the Mid Pharma peer set - Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe Highlights of this title: - Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the Big 6, CNS-focus, CV-focus, small domestic and multi-business unit clusters. - Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the Big 6 players located in the middle range, addressing a broad range of therapy areas. - Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier. Reasons to order your copy: - Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition - Identify which companies are appropriate licensing targets on the basis of their fit according to their scale, therapeutic and geographic focus - Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma

Contents: Chapter 1 Executive summary 4 Key findings 4 Mid Pharma – pharmaceutical companies with annual revenues under $10bn 6 Type of externalization strategy 10 Phase of externalization 11 Motives for external sourcing of products 11 Access to a broad palette of R&D opportunities 12 Externalization strategies as a mechanism for strategic redirection 12 Motives for source companies entering into externalization deals with Mid Pharma 12 Mid Pharma by revenues 13 Mid Pharma by therapy area 15 Segmentation analysis of Mid Pharma 16 Mid Pharma’s dependence on externalization 18 Mid Pharma externalization sub-analysis 20

Chapter 2 Mid pharma – committed to externalization as an r&d strategy 31 Mid Pharma – pharmaceutical companies with annual revenues under $10bn 33

Concept of external sourcing 40 Type of externalization strategy 41 Phase of externalization 42 Sample analysis of when externalization deals are actually executed 43 Motives for external sourcing of products 45 The cost of externalized R&D vs. internal R&D 45 Access to a broad palette of R&D opportunities 46 Externalization strategies as a mechanism for strategic redirection 46 Motives for source companies entering into externalization deals with Mid Pharma 46

Chapter 3 Mid pharma segmentation 48 Mid Pharma by company 50 >$4 billion companies 51 $2–4 billion companies 51 <$2 billion companies 52 Mid Pharma company sales forecast 56 Mid Pharma company growth forecast 58 Mid Pharma by therapy area 59 Mid Pharma therapy area sales forecast 62 Mid Pharma therapy area growth forecast 63 Mid Pharma companies by CNS focus 65 Mid Pharma companies by cardiovascular focus 66 Mid Pharma segmentation by therapy area and size 69 Mid Pharma by geography 73

Chapter 4 Mid pharma externalization analysis 78 Mid Pharma externalization analysis 79 Externalization dependency by company 81 Segmentation of companies by externalization dependency 83 Company forecast for externalized products 87 Externalization dependency by therapy area 89 Therapy area forecast for externalized products 92 Domestic versus multi-region players 94 European Licensing Specialists 96 US Licensing Specialists 99

Chapter 5 Mid pharma externalization sub-analysis 103 Mid Pharma externalization sub-analysis 104 Externalization revenues by deal type 105 Companies by externalization deal type 107 Marketing & development deals 108 Co-marketing deals 109 Co-promotion deals 110 Marketing deals 111 M&A deals 112

Chapter 6 Appendix: supporting data 114 Exchange rates List of Tables Table 1: Mid Pharma companies ranked by sales, 2005 6 Table 2: Proportion of total sales by deal type, 2005 22 Table 3: Mid Pharma companies ranked by sales, 2005 33 Table 4: The PharmaVitae Mid Pharma peer set 50 Table 5: Mid Pharma therapy area sales, 2005 59 Table 6: Menarini’s key domestic licensing deals 97

Table 7: Almirall’s Top 10 domestic licensing deals 98 Table 8: Forests Major Licensing Deals 100 Table 9: King’s Major Licensing Deals 101 Table 10: Proportion of total sales by deal type, 2005 106 Table 11: Exchange rates*, 2004 List of Figures Figure 1: Mid and Big Pharma CAGRs, 2001–04, 2004–07f and 2007f–10f 7 Figure 2: % Dependency of revenues on externally sourced products 8 Figure 3: Absolute growth ($bn) of Mid Pharma peer set, 2005–10f 9 Figure 4: Mid Pharma ranked by 2005 ethical sales 13 Figure 5: Big Pharma vs. Mid Pharma therapy area split 15 Figure 6: Segmentation of Mid Pharma by therapy area focus and size ($m), 2005 16 Figure 7: Mid Pharma sales by source, 2001–10f 18 Figure 8: Mid Pharma external discovery revenue dependency, 2005 19 Figure 9: Mid Pharma externally sourced sub-classification 21 Figure 10: Mid Pharma external discovery sales by deal type, 2005 21 Figure 11: Mid Pharma company by externalization deal type, 2005 23 Figure 12: Mid & Big Pharma ethical sales, 2001–10f 34 Figure 13: Mid and Big Pharma CAGRs, 2001–04, 2004–07f and 2007f–10f 35 Figure 14: CAGRs for Mid Pharma peer set, 2004–10f 36 Figure 15: % Dependency of revenues on externally sourced products 38 Figure 16: Absolute growth ($bn) of Mid Pharma peer set, 2005–10f 39 Figure 17: A product is defined as externally sourced on the basis of being discovered in an external R&D pipeline 40 Figure 18: Stage of licensing for top 50 deals in terms of 2005 revenues 43 Figure 19: Mid Pharma ranked by 2005 ethical sales 54 Figure 20: Mid Pharma historical and sales forecasts, 2001–10f 56 Figure 21: Mid Pharma absolute growth, 2005–10f 58 Figure 22: Big Pharma vs. Mid Pharma therapy area split 61 Figure 23: Mid Pharma sales by therapy area, 2005 62 Figure 24: Mid Pharma absolute growth by therapy area, 2005–10f 63 Figure 25: Percentage of 2005 sales derived from CNS products for Mid Pharma 65 Figure 26: Percentage of 2005 sales derived from CV products for Mid Pharma 66 Figure 27: Percentage of revenues from top four therapy areas, 2005 67 Figure 28: Distribution of CNS- and CV-focused players 68 Figure 29: Segmentation of Mid Pharma by therapy area focus and size ($m), 2005 69 Figure 30: Segmentation of Mid Pharma by therapy area focus and size ($m), 2010f 71 Figure 31: Mid Pharma 2005 revenues by geography 73 Figure 32: Mid Pharma ranked by US focus, 2005 74 Figure 33: Classification of Mid Pharma peer set 76 Figure 34: Mid Pharma sales by source, 2001–10f 79 Figure 35: Absolute growth ($bn) of Mid Pharma peer set by source, 2005–10f 80 Figure 36: Mid Pharma external discovery revenue dependency, 2005 81 Figure 37: Segmentation of Mid Pharma by externalization dependency and size, 2005 83 Figure 38: Mid Pharma externally sourced revenues by company, 2005 85 Figure 39: Mid Pharma revenues from externally source products by company, 2001–10f 87 Figure 40: Externalization dependency by therapy area 89 Figure 41: Mid Pharma 2005 externally sourced sales by therapy area, 2005 91 Figure 42: Externally sourced revenues by therapy area, 2001–10f 92 Figure 43: Regional focus of Mid Pharma externalization 94 Figure 44: Mid Pharma externally sourced sub-classification 104 Figure 45: Mid Pharma external discovery sales by deal type, 2005 105 Figure 46: Mid Pharma company by externalization deal type, 2005 107 Figure 47: Proportion of externally sourced sales from marketing & development, 2005 108 Figure 48: Proportion of externally sourced sales from co-marketing, 2005 109 Figure 49: Proportion of externally sourced sales from co-promotion, 2005 110 Figure 50: Proportion of externally sourced sales from marketing, 2005 111 Figure 51: Proportion of externally sourced sales from corporate M&A, 2005 112

Ordering:

Order Online - http://www.researchandmarkets.com/reports/340358/

Order by Fax - using the form below Order by Post - print the order form below and sent to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

Page 1 of 2 Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-6071907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Mid Pharma Sector: In-licensing and Other Externalization Strategies http://www.researchandmarkets.com/reports/340358/ OC8HKINQRSWUU

Product Formats
Please select the product formats and quantity you require: Quantity Electronic: Electronic: EURO €5,300.00 EURO €13,250.00

Contact Information
Please enter all the information below in BLOCK CAPITALS Title: First Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL) Mr Mrs Dr Miss Last Name: Ms Prof

Page 2 of 2 Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: American Express Diners Club Master Card Visa Cardholder's Name Cardholder's Signature Expiry Date Card Number CVV Number Issue Date
(for Diners Club only)

Pay by check:

Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address 833 130 83 98-53-30 ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

Pay by wire transfer:

If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353 1 481 1716 or +353 1 653 1571 - From Rest of World


								
To top